SUPHA PHARMACHEM LIMITED

BSE: SUPHA539561ISIN INE549S01036

Services
Trading & Distributors

Share price

₹0.26+0.01 (+4.00%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded. Earlier history is omitted pending corporate-action verification.

52W high: ₹1.66
52W low: ₹0.23
Off 52W high: -84.34%
1M return: +4.00%
3M return: -21.21%
6M return: -40.91%
1Y return: -83.65%
20D avg volume: 17,08,500
50 DMA: ₹0.26
200 DMA: ₹0.46

Key ratios Consolidated

Market cap: ₹22.93 Cr
Current price: ₹0.26
52W high / low: ₹1.66 / ₹0.23
Face value: ₹1.00
P/E: 0.00
P/B: 0.22
EPS (TTM): ₹0.00
Book value / share: ₹1.19
ROE: —
ROCE: 22.00%
Operating margin: —
Net margin: —
Debt / equity: 26.01
Net debt: ₹1,141 Cr
Interest cover: 1.83
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 486.4 days

Financials

Metric	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	111.06	113.37	264.32	—
	3.25	3.48	0.66	—
	114.31	116.84	264.98	—
	103.88	111.13	266.38	—
	0.00	0.00	0.00	—
	98.03	101.69	191.01	—
	0.19	0.20	0.09	—
	0.19	0.36	1.59	—
	0.00	0.00	0.01	—
	3.02	3.47	2.02	—
	10.44	5.71	-1.40	—
	0.00	0.00	0.00	—
	10.44	5.71	-1.40	—
	1.81	1.06	0.65	—
	8.62	4.65	-2.05	—
	0.10	0.05	-0.05	—
Key metrics
	10.63	6.07	0.20	—
	9.60%	5.40%	0.10%	—
	7.80%	4.10%	-0.80%	—
	10.10%	—	0.40%	—

Metric	FY25	FY24
Income statement
	405.25	—
	10.80	—
	416.05	—
	411.67	—
	0.00	—
	534.28	—
	0.76	—
	5.29	—
	0.04	—
	7.45	—
	4.38	—
	0.00	—
	4.38	—
	2.25	—
	2.13	—
	0.05	—
Key metrics
	9.71	—
	2.40%	—
	0.50%	—
	22.00%	—
	-1,135	—
	-532.77	—
	26.01	—
	1,141	—
	486.4	—
Balance sheet
	1,720	—
	1,720	—
	0.28	—
	771.62	—
	269.38	—
	2.50	—
	0.01	—
	500.96	—
	1,676	—
	1,141	—
	1,141	—
	0.00	—
	43.89	—
Cash flow
	-1,135	—
	0.13	—
	1,136	—
	0.00	—

Metric	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24
Income statement
	8.58	18.37	81.57	38.15	25.08	77.70	1,408	1,834	468.57	330.46
	3.25	3.48	0.66	7.43	0.82	1.89	2.89	14.12	4.08	—
	11.83	21.85	82.23	45.58	25.90	79.59	1,411	1,848	472.65	330.46
	11.76	22.22	84.35	44.52	23.45	77.32	1,447	1,780	462.24	323.20
	0.00	0.00	0.00	—	—	—	—	—	—	—
	5.91	12.81	8.98	77.70	115.39	150.18	1,422	1,892	495.42	318.30
	0.19	0.20	0.09	0.20	0.24	0.22	0.18	0.17	0.21	0.28
	0.19	-0.36	1.59	0.88	2.81	—	3.85	0.03	—	—
	0.00	0.00	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
	3.02	3.43	2.01	2.47	0.07	1.01	1.72	0.00	2.31	0.06
	0.07	-0.37	-2.12	1.06	2.46	2.27	-36.00	68.78	10.40	7.27
	0.00	0.00	0.00	—	—	—	—	—	—	—
	0.07	-0.37	-2.12	1.06	2.46	2.27	-36.00	68.78	10.40	7.27
	0.00	0.00	0.52	0.29	0.68	0.63	17.72	—	3.88	2.02
	0.07	-0.37	-2.64	0.76	1.77	1.64	-53.72	68.78	6.53	5.25
	0.00	0.00	-0.07	0.02	0.04	0.16	-5.33	34.12	6.48	14.57
Key metrics
	0.26	-0.73	-0.52	1.95	5.28	2.28	-32.14	68.82	10.41	7.28
	3.00%	-4.00%	-0.60%	5.10%	21.10%	2.90%	-2.30%	3.80%	2.20%	2.20%
	0.80%	-2.00%	-3.20%	2.00%	7.10%	2.10%	-3.80%	3.70%	1.40%	1.60%
	0.30%	—	-1.20%	—	—	—	—	—	—	—
	-65.80%	-76.40%	-94.20%	-97.90%	-94.60%	-76.50%	—	—	—	—
	-96.00%	-122.60%	95.10%	-98.90%	-72.90%	-68.80%	—	—	—	—

Metric	TTM	FY25	FY24
Income statement
	146.67	222.50	4,042
	14.82	10.80	21.08
	161.49	233.30	4,063
	162.85	229.64	4,012
	—	0.00	—
	105.40	352.26	4,127
	0.68	0.76	0.84
	2.30	5.29	3.87
	0.02	0.04	0.06
	10.93	7.44	6.19
	-1.36	3.67	50.45
	—	0.00	—
	-1.36	3.67	50.45
	0.81	2.13	17.72
	-2.18	1.53	32.73
	-0.05	0.04	3.25
Key metrics
	0.96	9.00	54.38
	0.65%	4.00%	1.30%
	-1.49%	0.70%	0.80%
	—	20.70%	—
	-95.62%	-94.50%	—
	-111.80%	-95.30%	—
	—	-1,079	—
	—	-704.99	—
	—	26.36	—
	—	1,141	—
	—	884.7	—
Balance sheet
	—	1,540	—
	—	1,540	—
	—	0.28	—
	—	590.92	—
	—	269.38	—
	—	2.50	—
	—	0.01	—
	—	320.98	—
	—	1,496	—
	—	1,141	—
	—	1,141	—
	—	0.00	—
	—	43.30	—
Cash flow
	—	-1,079	—
	—	0.06	—
	—	1,078	—
	—	0.00	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -95.62%
Profit YoY (TTM): -111.80%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Redington Limited	28,660	366.60	18.17	19.00%	+31.26% TTM	-17.17% TTM	+46.46%
MMTC Ltd.	8,025	53.50	17.94	21.60%	-19.71% TTM	+355.55% TTM	-20.53%
MSTC Limited	4,106	583.25	17.52	31.80%	+21.02% TTM	-44.88% TTM	+6.22%
CREATIVE NEWTECH LIMITED	2,094	1,394.20	25.97	26.40%	—	—	—
Pervasive Commodities Limited S	1,137	12.62	74.24	0.00%	+111.30% TTM	+197.12% TTM	—
BN AGROCHEM LIMITED	1,117	114.20	65.40	4.20%	+84.51% TTM	-60.97% TTM	-68.29%
RRP DEFENSE LIMITED S	802	584.75	-330.37	-8.00%	+39.37% TTM	-364.13% TTM	-35.71%
The Yamuna Syndicate Ltd	750	24,400.00	8.22	0.30%	+11.33% TTM	-16.43% TTM	-32.22%
Shiv Aum Steels Limited	741	545.00	—	—	—	—	—
Riddhi Siddhi Gluco Biols Ltd	636	670.90	-27.71	2.80%	-37.98% TTM	+38.40% TTM	+20.31%
State Trading Corporation of India	624	104.00	—	-16.70%	—	—	-21.92%
Arvaya Healthcare Limited S	569	118.45	-311.71	-2.10%	-47.37% TTM	-2,742.86% TTM	+148.22%
Oswal Agro Mills Ltd.	548	40.86	-15.96	1.50%	-99.98% TTM	-127.15% TTM	-46.29%
SMT ENGINEERING LIMITED	459	254.15	18.72	24.80%	+248.17% TTM	+377.43% TTM	+169.03%
Filtron Engineers Ltd. S	451	71.04	1,420.80	0.30%	-100.00% TTM	+363.64% TTM	+67.00%
Kothari Products Ltd.	364	61.00	18.72	1.60%	+7.57% TTM	+124.93% TTM	-32.00%
Balgopal Commercial limited	337	145.00	-62.76	-12.50%	-96.08% TTM	-231.62% TTM	-35.47%
PIPAN OILS LIMITED S	323	184.25	-118.11	-191.70%	—	-1,342.11% TTM	+35.19%
VEGA JEWELLERS LIMITED S	315	61.95	10.45	31.50%	+465.43% TTM	+873.55% TTM	+60.24%
Novalum Materials Limited S	307	46.74	274.94	7.70%	+290.48% TTM	+239.39% TTM	+36.63%
Sakuma Exports Ltd.	285	1.82	26.72	1.80%	-13.44% TTM	-0.93% TTM	-34.53%
Parshva Enterprises Limited	254	249.05	950.47	3.60%	+0.24% TTM	+8.33% TTM	+32.09%
Polo Queen Industrial and Fintech Limited	253	7.54	110.89	2.50%	-2.02% TTM	-15.56% TTM	-79.87%
Sicagen India Limited	225	56.94	8.91	7.40%	+29.43% TTM	+50.03% TTM	-9.42%
Chandrima Mercantiles limited S	218	6.55	-163.75	4.30%	-69.52% TTM	-134.73% TTM	-34.63%
SUPHA PHARMACHEM LIMITED S	23	0.26	-13.00	20.70%	-95.62% TTM	-111.80% TTM	-83.65%

Filings & corporate actions

Recent announcements

Disclosure under Regulation 30 of SEBI (LODR), 201530 Jun 2026 · Company Update / General
Intimation for closure of Trading Window27 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Appointment of Resolution Professional in place of Interim Resolution Professional12 May 2026 · Company Update / General
Disclosure to take note of decisions taken in 1st COC meeting held on 14.04.202617 Apr 2026 · Company Update / General
This disclosure is to place on record List of Creditors as required to be placed under Reg 13(2)(c) of IBBI CIRP Regulations10 Apr 2026 · Company Update / List of Creditors
Update on CIRP Proceedings, Non-Cooperation by Directors (Power suspended) and Postponement of Board Meeting under Regulation 30 of SEBI (LODR) Regulation, 20152 Apr 2026 · Company Update / General
Closure of Trading window25 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of receipt of Order from National Company Law Tribunal (NCLT)21 Mar 2026 · Company Update / General
Submission of Form A - PUBLIC ANNOUNCEMENT20 Mar 2026 · Company Update / General
Intimation for Admission of Co. under CIRP and appointment of IRP19 Mar 2026 · Company Update / Appointment of Interim Resolution Professional (IRP)
Intimation of change in registered office of the company to office no. F81D, Express Zone Mall, A wing Next to Patel Vanika, W.E. Highway, Goregaon, (East), Mumbai - 400063, w.e.f. 17th ....17 Mar 2026 · Company Update / General
Supha Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/03/2026 ,inter alia, to consider and approve To consider Un-Audited Financial ....9 Mar 2026 · Company Update / Board Meeting Rescheduled
Supha Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/03/2026 ,inter alia, to consider and approve unaudited standalone and consolidated ....25 Feb 2026 · Company Update / Board Meeting Rescheduled
Supha Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 ,inter alia, to consider and approve unaudited standalone and consolidated ....17 Feb 2026 · Company Update / Board Meeting Rescheduled
Rescheduling on 25/02/202614 Feb 2026 · Company Update / General
Demise of CS and Compliance Officer14 Feb 2026 · Company Update / Demise
Supha Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Un-Audited Financial Results/Statements ....3 Feb 2026 · Board Meeting / Board Meeting
Submission of Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31.12.202520 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of closure of Trading Window22 Dec 2025 · Insider Trading / SAST / Closure of Trading Window
Company is pleased to informed that MCA has approved the change of name vide certificate of incorporation W.E.F. 15/12/2025 from REMEDIUM LIFECARE LTD. TO SUPHA PHARMACHEM LIMITED15 Dec 2025 · Company Update / Change of Name
Submission of postal ballot results and scrutinizer report8 Dec 2025 · AGM/EGM / Postal Ballot
Submission of outcome of postal ballot8 Dec 2025 · AGM/EGM / Postal Ballot
Newspaper Publication for unaudited financial results 30.09.202517 Nov 2025 · Company Update / Newspaper Publication
Remedium Lifecare Delivers Strong Q2 Results with Profit Nearly Doubling to Rs.862.34 Lakh17 Nov 2025 · Company Update / Press Release / Media Release
Financial Results for Quarter and Half Year ended September 30, 202514 Nov 2025 · Result / Financial Results
Board Meeting Outcome for The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter and Half year Ended September 30, 202514 Nov 2025 · Board Meeting / Outcome of Board Meeting
Remedium Lifecare Strengthens Leadership for Next-Phase Growth10 Nov 2025 · Company Update / Press Release / Media Release
Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve Unaudited Standalone and ....6 Nov 2025 · Board Meeting / Board Meeting
Newspapers publication for dispatch of postal ballot notice6 Nov 2025 · Company Update / Newspaper Publication
Submission of postal ballot notice4 Nov 2025 · AGM/EGM / Postal Ballot
Appointment31 Oct 2025 · Company Update / General
the Board in ite metting approved 1. Appointed Mr. Rambhajan Vishwakarma . 2. Appointed Mr. Vignesh Laxman Gawde . 3. Approved the Postal Ballot notices 4. The Board has reconstituted ....31 Oct 2025 · Others / Outcome without intimation
Resignation of Mr. Mansoor Abdul Vahab29 Oct 2025 · Company Update / Resignation of Director
Compliance certificate under Reg. 74(5) of SEBI (DP) 30.09.202510 Oct 2025 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Resignation of Mr. Dipesh Vaidya Non- Executive Independent Director6 Oct 2025 · Company Update / Resignation of Director
e-voting results of AGM and scrutinizer Report of AGM held on 24.09.2025 through VC/OAVM24 Sep 2025 · AGM/EGM / AGM
Proceedings of 36th AGM held on 24.09.2025 through VC/OAVM24 Sep 2025 · AGM/EGM / AGM
Intimation of closure of trading window23 Sep 2025 · Insider Trading / SAST / Closure of Trading Window
We wish to inform you that, the Board of Directors of the Company, at its meeting held today 22nd September, 2025 has inter- alia considered, approved and taken on record 1. Change of ....22 Sep 2025 · Board Meeting / Outcome of Board Meeting
Remedium Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/09/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 ....16 Sep 2025 · Board Meeting / Board Meeting

Corporate actions

Purpose	Ex date	Record date	Payment date
Right Issue of Equity Shares	15 Apr 2025	15 Apr 2025	—
Bonus issue 3:1	5 Jul 2024	6 Jul 2024	—